Market News & Trends
Foamix Announces Publication of Phase 3 FMX101 Study
Foamix Pharmaceuticals Ltd. recently announced the peer review publication of the Phase 3 study FX2017-22 (Study 22) in the Journal of the American Academy of…
Cytel & Axio Join Forces to Create Industry Leader in Analytical Solutions for Drug Development
Cytel Inc. and Axio Research recently announced they have joined forces to create the largest global biometrics organization focused on delivering advanced analytical solutions for…
BioXcel Therapeutics Announces FDA Clearance of IND Application
BioXcel Therapeutics recently announced an update of its immuno-oncology program for BXCL701, an orally available systemic innate-immune activator with dual mechanisms of action. BTI is…
Allena Pharmaceuticals Announces Interim Study Results
Allena Pharmaceuticals, Inc. recently announced interim data from Study 206, its Phase 2 basket clinical trial of reloxaliase, an orally administered, recombinant oxalate-degrading enzyme. Study…
VBI Vaccines Reports Data From Part A of the Ongoing Phase 1/2a Study
VBI Vaccines Inc. recently presented a poster at the American Society of Clinical Oncology (ASCO) Annual Meeting that exhibited expanded clinical data from Part A…
PCI Pharma Services Announces Further Expansion to Maintain Industry-Leading Quality, Service, and Flexibility
PCI Pharma Services, a leading biopharmaceutical outsourcing services provider, recently announced the growth of its West Coast Clinical operations with expansion into its third facility in San Diego.
Verseon Showcases Oral Candidates for Next-Generation Diabetic Eye Disease Drugs
Verseon recently presented a new class of oral candidate drugs, which could not only revolutionize the treatment of diabetic macular edema (DME), but could also be effective in preventing this increasingly common condition.
Cambrex Completes New Process & Analytical Development Facility
Cambrex Corporation recently announced it has completed a new facility at its site in Karlskoga, Sweden, which incorporates new laboratories for process and analytical development.
ABITEC Improves Solubility of Topical & Transdermal Applications With Functional Lipid Excipients
ABITEC Corporation, a global manufacturer of functional lipid excipients continues to pursue new technologies that solve various formulation challenges in the pharmaceutical market.
Treos Bio Announces Positive Interim Results from a Phase 1/2 Clinical Trial
Treos Bio Limited reported positive interim results from its first-in-man Phase 1/2 study of its precision cancer vaccine with maintenance therapy in patients with metastatic…
Nanobiotix Announces Launch of Nanotechnology Platform
NANOBIOTIX recently announced the launch of new subsidiary Curadigm, dedicated to redefining the therapeutic balance between bioavailability, toxicity, and efficacy across the pharmaceutical industry. The…
Up to 6 New HBV Drugs Set to Launch by 2027, With China Driving Market Growth
Within the next 10 years, up to 6 new drugs are projected to be approved for the treatment of chronic hepatitis B virus (HBV) infections…
Pfenex & Alvogen Announce EMA Accepts Marketing Authorization Application
Pfenex Inc. and Alvogen recently announced that the European Medicines Agency (EMA) has accepted the Marketing Authorization Application (MAA) submitted by our partner Alvogen for…
Mereo BioPharma Announces Positive Early 6-Month Data
Mereo BioPharma Group plc recently announced encouraging 6-month data from the open label arm of its Phase 2b dose-ranging clinical study in adults with Type…
Fluidigm Introduces Advanta RNA Fusions NGS Library Prep Assay
Fluidigm Corporation recently introduced the Advanta™ RNA Fusions NGS Library Prep Assay for detection of over 380 gene fusion pairs from solid tumors and hematological…
Sol-Gel Technologies Announces Seventh Agreement
Sol-Gel Technologies, Ltd. recently announced it has entered into a seventh collaborative agreement with Perrigo Israel, an affiliate of Perrigo Company plc for the development, manufacturing, and commercialization of two new generic formulations of antibiotic foams.
Biomunex Pharmaceuticals Establishes US Subsidiary
Biomunex Pharmaceuticals recently announced that it has established its US subsidiary, Biomunex Pharmaceuticals Inc., in Cambridge, MA.
Japan’s Medical Device Market Set to Reach $74.7 Billion in 2025
The Japanese medical device market is set to reach from $54.5 billion in 2018 to $74.7 billion in 2025, growing at a compound annual growth rate (CAGR) of 4.6% says GlobalData, a leading data and analytics company.
At-a-Glance, a New Way to Visualize Market Data
Tim McLean, Senior Editor, Life Sciences BCC Research, say his company’s new type of market research report is far shorter — but hopefully it delivers the bigger picture.
Catalent Completes Acquisition of Gene Therapy Leader for $1.2 Billion
Catalent, Inc. recently announced it has completed the $1.2-billion acquisition of Paragon Bioservices, Inc., a leading viral vector development and manufacturing partner for gene therapies.…
